Axitinib/Axitinib Medication Warning: Which drugs should be avoided taking together?

Axitinib (Axitinib) is a targeted therapy used to treat patients with advanced renal cell carcinoma, especially those whose disease has progressed despite other treatments. Axitinib inhibits the vascular endothelial growth factor receptor (VEGFR) and other related tyrosine kinases, thereby reducing the blood supply of tumors and inhibiting tumor growth and spread. Clinical trials have shown that axitinib can significantly extend progression-free survival (PFS) and overall survival (OS), making it an important treatment option.

During the use of axitinib, patients need to pay attention to possible drug interactions, especially drugs related to theCYP3A4/5 enzyme system. Axitinib is primarily metabolized by the CYP3A4/5 enzymes in the liver, therefore any drug that significantly affects these enzymes has the potential to alter axitinib plasma concentrations. For example, strong CYP3A4/5 inhibitors (such as ketoconazole) may increase the plasma exposure of axitinib, thereby increasing the risk of adverse effects, and it is recommended to avoid coadministration of axitinib with these strong inhibitors. In addition, grapefruit and its juice may also increase the plasma concentration of axitinib, and patients should try to avoid ingestion during treatment.

On the other hand, strong CYP3A4/5 inducers (such as rifampicin, dexamethasone, and phenytoin) may reduce the plasma levels of axitinib, leading to a decrease in its efficacy. Therefore, it is also crucial to avoid combined use with these inducers. When taking concomitant medications, patients should choose drugs that do not inhibit or induce CYP3A4/5 to ensure the stability and effectiveness of treatment.

In conclusion, axitinib has a significant effect in the treatment of advanced renal cell carcinoma, but its safety and efficacy may be affected by interactions with other drugs. When using axitinib, patients should follow their doctor's instructions, regularly monitor the plasma concentration of the drug, and carefully consult and evaluate possible drug interactions before use to ensure the best possible therapeutic effect.

Reference materials:https://www.pfizermedicalinformation.com/inlyta/drug-interactions